Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) EBITDA Margin: 2021

Historic EBITDA Margin for Atea Pharmaceuticals (AVIR) over the last 1 years, with Dec 2021 value amounting to 60.95%.

  • Atea Pharmaceuticals' EBITDA Margin was N/A to 60.95% in Q4 2021 from the same period last year, while for Dec 2021 it was 36.51%, marking a year-over-year change of. This contributed to the annual value of 34.49% for FY2021, which is 5700.00% up from last year.
  • Atea Pharmaceuticals' EBITDA Margin amounted to 60.95% in Q4 2021, which was up 170.93% from -85.93% recorded in Q3 2021.
  • Atea Pharmaceuticals' EBITDA Margin's 5-year high stood at 60.95% during Q4 2021, with a 5-year trough of -85.93% in Q3 2021.
  • For the 1-year period, Atea Pharmaceuticals' EBITDA Margin averaged around 8.97%, with its median value being 30.42% (2021).